Patents by Inventor Philippe Blancou

Philippe Blancou has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230142770
    Abstract: Devices and methods for the stimulation of neural signalling of an apical splenic nerve, the device having a transducer for placement on or around the apical splenic nerve, and a signal generator to generate a signal that stimulates or inhibits the neural activity of the apical splenic nerve to produce a physiological response. The transducer has at least one electrode, and the signal generator is a voltage or current source. The stimulation electrical signal has a frequency of between 1 Hz and 50 Hz.
    Type: Application
    Filed: January 6, 2023
    Publication date: May 11, 2023
    Inventors: Philippe Blancou, Nicolas GLAICHENHAUS, Arun SRIDHAR
  • Patent number: 11577082
    Abstract: Devices and methods for the stimulation of neural signaling of an apical splenic nerve, the device having a transducer for placement on or around the apical splenic nerve, and a signal generator to generate a signal that stimulates or inhibits the neural activity of the apical splenic nerve to produce a physiological response. The transducer has at least one electrode, and the signal generator is a voltage or current source. The stimulation electrical signal has a frequency of between 1 Hz and 50 Hz.
    Type: Grant
    Filed: November 8, 2017
    Date of Patent: February 14, 2023
    Assignees: Galvani Bioelectronics Limited, GlaxoSmithKline Intellectual Property Development Limited, Université de Nice Sophia-Antipolis, Centre Nationale de La Recherche Scientifique
    Inventors: Philippe Blancou, Nicolas Glaichenhaus, Arun Sridhar
  • Publication number: 20230030204
    Abstract: Modulation of neural signaling of a pancreas-related sympathetic nerve is capable of improving glycaemic control by inhibiting T cell activation or migration to the pancreas, and hence providing a way of treating or preventing type 1 diabetes.
    Type: Application
    Filed: October 17, 2022
    Publication date: February 2, 2023
    Inventors: Arun Sridhar, Philippe Blancou, Nicolas Glaichenhaus
  • Patent number: 11517754
    Abstract: Modulation of neural signaling of a pancreas-related sympathetic nerve is capable of improving glycaemic control by inhibiting T cell activation or migration to the pancreas, and hence providing a way of treating or preventing type 1 diabetes.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: December 6, 2022
    Assignees: Galvani Bioelectronics Limited, Centre Nationale de La Recherche Scientifique, Université Côte d'Azur
    Inventors: Arun Sridhar, Philippe Blancou, Nicolas Glaichenhaus
  • Publication number: 20210339025
    Abstract: Modulation of neural signaling of a pancreas-related sympathetic nerve is capable of improving glycaemic control by inhibiting T cell activation or migration to the pancreas, and hence providing a way of treating or preventing type 1 diabetes.
    Type: Application
    Filed: May 4, 2018
    Publication date: November 4, 2021
    Inventors: Arun SRIDHAR, Philippe BLANCOU, Nicolad GLAICHENHAUS
  • Patent number: 10751406
    Abstract: The present invention provides for novel compositions and methods for delivering genes of interest to stem cells using vectors that contain differentiation-specific transcriptional regulatory elements. For example, stem cells in the internal epithelia could be transfected with a vaccine construct, which has an epithelial cell differentiation-specific promoter driving the expression of viral envelope proteins. When the promoter used is specific for terminally differentiated epithelial cells, then the viral envelope proteins will be expressed only in the upper part of the epithelia and therefore, stimulate the immune response. The infected epithelial stem cells in the basal layer will continue to produce new antigen-expressing cells, without being eliminated by the immune response. This invention will be useful in the development of vaccines against viral agents that target the internal mucosa like HIV.
    Type: Grant
    Filed: August 8, 2017
    Date of Patent: August 25, 2020
    Assignee: TEXAS BIOMEDICAL RESEARCH INSTITUTE
    Inventors: Marie-Claire Gauduin, Philippe Blancou
  • Publication number: 20190290913
    Abstract: Stimulation of neural signalling of an apical splenic nerve can modulate pro- and anti-inflammatory molecules levels, thereby reducing inflammation and providing ways of treating inflammatory disorders.
    Type: Application
    Filed: November 8, 2017
    Publication date: September 26, 2019
    Applicants: GALVANI BIOELECTRONICS LIMITED, UNIVERSITÉ DE NICE SOPHIA-ANTIPOLIS, CENTRE NATIONALE DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Philippe BLANCOU, Nicolas GLAICHENHAUS, Arun SRIDHAR
  • Publication number: 20180177858
    Abstract: The present invention provides for novel compositions and methods for delivering genes of interest to stem cells using vectors that contain differentiation-specific transcriptional regulatory elements. For example, stem cells in the internal epithelia could be transfected with a vaccine construct, which has an epithelial cell differentiation-specific promoter driving the expression of viral envelope proteins. When the promoter used is specific for terminally differentiated epithelial cells, then the viral envelope proteins will be expressed only in the upper part of the epithelia and therefore, stimulate the immune response. The infected epithelial stem cells in the basal layer will continue to produce new antigen-expressing cells, without being eliminated by the immune response. This invention will be useful in the development of vaccines against viral agents that target the internal mucosa like HIV.
    Type: Application
    Filed: August 8, 2017
    Publication date: June 28, 2018
    Inventors: Marie-Claire Gauduin, Philippe Blancou
  • Publication number: 20180015101
    Abstract: The invention is in the field of immunotherapy. More particularly, the invention provides a composition comprising a Heme Oxygenase-1 (HO-1) and antigens. Also provided herein are methods of administering the compositions of the invention by subcutaneous, intradermal or topical administration in a patient for inducing antigen-specific tolerance.
    Type: Application
    Filed: October 27, 2015
    Publication date: January 18, 2018
    Inventors: Ignacio ANEGON, Philippe BLANCOU, Thomas SIMON, Julien POGU
  • Patent number: 9730996
    Abstract: The present invention provides for novel compositions and methods for delivering genes of interest to stem cells using vectors that contain differentiation-specific transcriptional regulatory elements. For example, stem cells in the internal epithelia could be transfected with a vaccine construct, which has an epithelial cell differentiation-specific promoter driving the expression of viral envelope proteins. When the promoter used is specific for terminally differentiated epithelial cells, then the viral envelope proteins will be expressed only in the upper part of the epithelia and therefore, stimulate the immune response. The infected epithelial stem cells in the basal layer will continue to produce new antigen-expressing cells, without being eliminated by the immune response. This invention will be useful in the development of vaccines against viral agents that target the internal mucosa like HIV.
    Type: Grant
    Filed: October 24, 2013
    Date of Patent: August 15, 2017
    Assignee: Texas Biomedical Research Institute
    Inventors: Marie-Claire Gauduin, Philippe Blancou
  • Publication number: 20140178426
    Abstract: The present invention provides for novel compositions and methods for delivering genes of interest to stem cells using vectors that contain differentiation-specific transcriptional regulatory elements. For example, stem cells in the internal epithelia could be transfected with a vaccine construct, which has an epithelial cell differentiation-specific promoter driving the expression of viral envelope proteins. When the promoter used is specific for terminally differentiated epithelial cells, then the viral envelope proteins will be expressed only in the upper part of the epithelia and therefore, stimulate the immune response. The infected epithelial stem cells in the basal layer will continue to produce new antigen-expressing cells, without being eliminated by the immune response. This invention will be useful in the development of vaccines against viral agents that target the internal mucosa like HIV.
    Type: Application
    Filed: October 24, 2013
    Publication date: June 26, 2014
    Applicant: Texas Biomedical Research Institute
    Inventors: Marie-Claire Gauduin, Philippe Blancou
  • Publication number: 20090142371
    Abstract: Reagents and methods for making and using HIV recombinant vaccines are disclosed.
    Type: Application
    Filed: August 21, 2008
    Publication date: June 4, 2009
    Applicant: Institut Pasteur
    Inventors: Simon Wain-Hobson, Philippe Blancou, Nicole Chenciner
  • Publication number: 20070065852
    Abstract: Reagents and methods for making and using HIV recombinant vaccines are disclosed.
    Type: Application
    Filed: August 30, 2006
    Publication date: March 22, 2007
    Inventors: Simon Wain-Hobson, Philippe Blancou, Nicole Chenciner
  • Publication number: 20030175693
    Abstract: Reagents and methods for making and using HIV recombinant vaccines are disclosed.
    Type: Application
    Filed: October 11, 2002
    Publication date: September 18, 2003
    Inventors: Simon Wain-Hobson, Philippe Blancou, Nicole Chenciner